In vitro to clinical translation of combinatorial effects of doxorubicin and dexrazoxane in breast cancer: a mechanism-based pharmacokinetic/pharmacodynamic modeling approach

Dexrazoxane (DEX) is the only drug clinically approved to treat Doxorubicin-induced cardiotoxicity (DIC), however its impact on the anticancer efficacy of DOX is not extensively studied. In this manuscript, a proof-of-concept in vitro study is carried out to quantitatively characterize the anticance...

Descripción completa

Detalles Bibliográficos
Autores principales: Mody, Hardik, Vaidya, Tanaya R., Lezeau, Jovin, Taha, Kareem, Ait-Oudhia, Sihem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620511/
https://www.ncbi.nlm.nih.gov/pubmed/37927589
http://dx.doi.org/10.3389/fphar.2023.1239141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620511/
https://www.ncbi.nlm.nih.gov/pubmed/37927589
http://dx.doi.org/10.3389/fphar.2023.1239141

Ejemplares similares